Spyros Triantos

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

Yohann Loriot, Nobuaki Matsubara, Se Hoon Park et al. · New England Journal of Medicine · 2023 · 291 citations

Medicine, Oncology, Pharmacology +15

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer

James W.F. Catto, Ben Tran, Morgan Rouprêt et al. · Annals of Oncology · 2023 · 78 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (<i>FGFRalt</i>).

Yohann Loriot, Nobuaki Matsubara, Se Hoon Park et al. · Journal of Clinical Oncology · 2023 · 44 citations

Medicine, Oncology, Pharmacology +13

A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer

Bradley J. Monk, Thomas J. Herzog, George Wang et al. · Gynecologic Oncology · 2020 · 43 citations

Medicine, Oncology, Pharmacology +15